The pneumonia diagnosis and treatment plan for novel coronavirus infection (trial fourth edition) released by the National Health Commission on January 27 mentioned the participation of intestinal microecological regulators in the treatment plan for novel coronavirus. On February 5, the fifth edition of the diagnosis and treatment program again mentioned that intestinal microbial modulators can be used for other treatment measures in severe and critical cases.
Li lanjuan, director of the National Key Laboratory for the diagnosis and treatment of infectious diseases, also mentioned many times that most critically ill patients in this outbreak have intestinal flora disorders. Moreover, it reaffirmed the helpful role of microecological preparations in the prevention and treatment of the epidemic, regulated the intestinal microecological balance, and reduced bacterial secondary infection.
Source: Shanghai Securities News
- White Paper on Bone and Joint Health of Chinese Consumers 2020
- Yili Dairy launched high-protein yogurt, focusing on sport people
- Sinopharm Xingsha launched the Japan's Champion probiotics
- China has introduced its first policy to support the industrial hemp industry
- Beyond Meat became the first overseas Artificial Meat company to set up a factory in China
- Nongfu Spring's market value exceeded HK $370 billion on its first day
- German infant nutrition brand Amykon launched two probiotics in China
- The revenue of Besunyoung in the first half year is about 610 million yuan
- Jellly candy and powder included in the health food filing dosage form in China
- H&H Group net profit increased by 9% for the first half of year
